Video Transcription
Mathieu Rimaud 00:02
Good afternoon, everybody. Thanks for being here. I'm really happy, and thanks for this opportunity to present you preoperative planning solutions using dynamic digital twins. I am Mathieu Rimaud, CEO and co-founder of Twinsight, which is a company providing a SaaS platform dedicated to supporting surgeons and improving patient care. As you know, the joint replacement market is huge, and among that, the knee replacement market is even bigger, growing even faster. It represents more than 10 billion euros per year, and it's about 1 million American citizens who get a total knee replacement each year. Unfortunately, there are too many unhappy patients, and that's kind of the nightmare that all surgeons have in mind. The funny fact is that all these knees are operated on by the most experienced surgeons, the ones who are doing the most important volumes, and in fact, what's happening in their mind. For many years, they have been using a dogmatic alignment that was super efficient in the operating room; all the patients were operated on the same way. Unfortunately, they can't control the outcomes, and that's why they're starting to try to find the best compromise, but this often ends up being a pure nightmare. So technology arrives, giving them even more information. But the fact is that this has demonstrated no clinical value. In fact, this is because we are basically not combining the precision of the planning with the accuracy of a robot. I make a stupid analogy: it's a bit like if you got a brand new Tesla and put an old tire on it. So it's kind of frustrating. And the consequences are huge. First, there is no improvement. This is demonstrated in publications, and these multiple investments are basically wasted because it remains 1 billion euros of extra money spent by the healthcare system to support all these unhappy patients, who are, in fact, unhappy and getting just frustrated as well, just because it's difficult for them to flex their knees or get pain when they climb the stairs. So what's the solution? Then it's basically to put more weight in the planning. And all this could have more impact. It is to provide new solutions, to balance this kind of unknown zone, and that's what we will bring through using a clone of the patient, using what we call the digital twin, and that's basically where our solution comes from. Our product is called 30 Twin, and it's a SaaS platform that will combine the pre-op imaging of the patient, which will then be combined, excuse me, with a reference model. Once this allows us to build the digital twin of the patient, then, using the implant database available in only five minutes, we will be able to provide an automatic and augmented planning with simple values that are new for the surgeon, like ligament balancing or patella tracking. Then the surgeon will easily review it, adjust it, and validate it. The advantage for them is that now they can think with augmented tools before the surgery and then consider everything in mind to be sure the surgery will be executed in a safe way. Advantages are multiple. This is safer for the surgeon. There is less risk for the patient with improved patient quality of care, but also for the healthcare system and the hospital, because there is a decrease in extra costs. So why is nobody using it today? Why is it not present on the market? First, because it took us more than 10 years of research to create a complex human body reference model. This is a combination of multiple expertise and skills, and that's why we ended up with this complex human body. Unfortunately, we surgeons can't use it as it is; it's not scalable. And that's why there is a second part of our secret sauce, which is coming. First of all, we will, in our secret sauce, excuse me, make it automatic and usable in the daily practice for a surgeon. First of all, we will build the patient anatomy thanks to AI that will then landmark and also cross-match with our own made algorithm in order to get the patient anatomy with also a functional knee. What I call a functional knee means that we are able to make the knee move and get all the other tissues which are important to make the right planning and loading with the implants. We will be able then to make the phenol to predict how the knee will be with this implant. So what about competition? Most of the players have a planning solution, and unfortunately, it's not enough. And what basically I would like to demonstrate here is that all of them, we can leverage their solutions combined with our industrial software components to bring the planning to the next stage. And that's why all of these guys are much more potential partners than true competitors. Our roadmap is pretty clear. We have already discussed with the FDA, closing our pre-sub meeting. We expect to have a 510(k) clearance by the end of next year, by mid-next year, excuse me, which will allow us to collect more data and then anticipate and develop what will be our second version, being even more predictive on the results. As we have the SaaS platform, we can easily target the most expert surgeons and the most expert centers to be able to reach them and generate annual revenues. By 2027, we expect to close more than 12,000 cases with 5 million euros of actual annual recurring revenues. Our go-to-market strategy is focused on the US first. We are going to define our first 10 users in the pre-search, in continuation of what we already started with our local resources over there, in order to define what will be our first users, but also first customers through the pay-per-use model. Then we will pursue the adoption through the new community. In the meantime, we will close some deals with the implant manufacturers or technology manufacturers, either for partnership or distribution. Of course, this technology could be extended to other joints, and the next one on the list is definitely the foot and ankle. In order to make it happen, we have a strong team. First of all, my three other co-founders and I have been dedicated to Twinsight for the last five years. We are based in France, and we have a strong team that is able to develop, support, and sell 30 Twin, our IP, which is 100% owned. We are ISO 13485 certified. We are also members of some startup programs, and we closed last year a pre-seed round of 0.6 million euros, mainly with experts and surgeons. Some of them are really well-known, and they are currently supporting us, and they are also our next pilot centers. I will cite Professor Parat, Dr. Van Nova Shield, and also Hôpital La France, Simon Paris, which is number one in France for hip, knee, and foot surgeries. As a wrap-up, I would say that we have a strong operational team, and we are dedicated to elevate the dimension of knee orthopedic surgery, starting with the knee, to the next level. We also have a fully scalable solution as it is software, and we are ready to move to the next stage for that. We are just opening our next seed round for 3 million euros, which we will build well balanced between commercial deployment for the US regulatory and the future development of our second version of the software. I really thank you for your attention, and I remain available if you want to discuss more, if you want to be part of this journey, and if you really want to think about how uniquely we will operate, thanks to unique digital twins. Thank you. Applause.
